Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MediWound (MDWD) stocks in Canada

Learn how to easily invest in MediWound stocks.

MediWound is a biotechnology business based in the US. MediWound stocks (MDWD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.33 – a decrease of 11.67% over the previous week. MediWound employs 75 staff and has a trailing 12-month revenue of around $24.9 million.

How to buy shares in MediWound

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDWD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MediWound stock price (NASDAQ:MDWD)

Use our graph to track the performance of MDWD stocks over time.

MediWound shares at a glance

Information last updated 2022-01-17.
Latest market close$2.65
52-week range$2.20 - $6.22
50-day moving average $2.74
200-day moving average $3.68
Wall St. target price$6.92
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy MediWound stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

MediWound price performance over time

Historical closes compared with the close of $2.65 from 2022-01-19

1 week (2022-01-13) -11.67%
1 month (2021-12-20) 12.77%
3 months (2021-10-20) -27.20%
6 months (2021-07-20) -39.77%
1 year (2021-01-20) -51.11%
2 years (2020-01-17) -12.54%
3 years (2019-01-18) 4.38
5 years (2017-01-20) 5.15

Is MediWound under- or over-valued?

Valuing MediWound stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MediWound's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MediWound's EBITDA

MediWound's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.2 million.

The EBITDA is a measure of a MediWound's overall financial performance and is widely used to measure a its profitability.

MediWound financials

Revenue TTM $24.9 million
Gross profit TTM $7.5 million
Return on assets TTM -21.04%
Return on equity TTM -285.27%
Profit margin -44.58%
Book value $0.08
Market capitalisation $78.7 million

TTM: trailing 12 months

MediWound share dividends

We're not expecting MediWound to pay a dividend over the next 12 months.

MediWound share price volatility

Over the last 12 months, MediWound's shares have ranged in value from as little as $2.2 up to $6.22. A popular way to gauge a stock's volatility is its "beta".

MDWD.US volatility(beta: 1.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MediWound's is 1.5251. This would suggest that MediWound's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MediWound overview

MediWound Ltd. , a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site